Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Henry ScheinHSIC +1.11%81 EV-to-EBIT is 21.54 as of Jul. 25, 2026, which is 14% above its 10-year median of 18.97. GuruFocus rates HSIC with a GF Score™ of 81/100 and a GF Value™ of $84.11 (Fairly Valued). The stock has 9 warning signs investors should review. Among 94 Medical Distribution companies, Henry Schein ranks worse than 78.72% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Henry Schein's Enterprise Value for the quarter that ended in Mar. 2026 was $13,600 Mil.
Henry Schein's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $692 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henry Schein EV-to-EBIT Related Terms
Henry Schein EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Henry Schein's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Henry Schein's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Henry Schein EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Henry Schein's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Henry Schein's EV-to-EBIT falls into.
Henry Schein's current Enterprise Value is $14,903 Mil.
Henry Schein's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $692 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henry Schein (HSIC) has a EV-to-EBIT of 21.54 as of Jul. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Henry Schein and its competitors. This is 14% above median its historical median of 18.97. Over the past decade, Henry Schein's EV-to-EBIT has ranged from 11.54 to 26.96. According to the industry distribution chart, Henry Schein ranks #74 out of 94 companies in the Medical Distribution industry, placing it in the top 78.7%.
Is Henry Schein's EV-to-EBIT too high?
Henry Schein's current EV-to-EBIT of 21.54 is 14% above median its 10-year median of 18.97. Over the past 10 years, this metric has ranged from a low of 11.54 to a high of 26.96. The Medical Distribution industry median EV-to-EBIT is 11.48. Henry Schein's value of 21.54 is 87.7% above this industry median. Based on the distribution chart, Henry Schein ranks #74 out of 94 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Henry Schein has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Henry Schein's EV-to-EBIT compare to AHG and ACH?
According to the Medical Distribution industry distribution chart, Henry Schein ranks #74 out of 94 companies for EV-to-EBIT. This places Henry Schein in the lower half of its industry. The industry median EV-to-EBIT is 11.48. Henry Schein's value of 21.54 is 87.7% above this benchmark. Historically, Henry Schein's own EV-to-EBIT has ranged from 11.54 to 26.96 over the past decade. While the company's 10-year median is 18.97 vs. the industry median of 11.48, Henry Schein has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.48, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Henry Schein's current EV-to-EBIT of 21.54 is 87.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Henry Schein and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Henry Schein's current EV-to-EBIT is 21.54, which is 14% above median its own 10-year median of 18.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henry Schein stock overvalued right now?
Based on GuruFocus' analysis, Henry Schein (HSIC) is currently considered Fairly Valued. The stock's GF Value™ is $84.11, compared to a current price of $85.47 — trading 1.6% above its estimated fair value. The current EV-to-EBIT is 21.54, which is 14% above median its 10-year median of 18.97 and 87.7% above the Medical Distribution industry median of 11.48. Henry Schein's overall GF Score™ is 81/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Henry Schein (HSIC), the current EV-to-EBIT is 21.54 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Henry Schein (HSIC) Overvalued in 2026?
Based on GuruFocus' analysis, Henry Schein stock appears to be overvalued.
The current stock price of $85.47 is trading 1.6% above its estimated GF Value™ of $84.11.
GuruFocus considers Henry Schein to be Fairly Valued.
Key valuation signals for HSIC:
EV-to-EBIT: 21.54 (14% above median its 10-year median of 18.97)
GF Value™: $84.11 vs. price of $85.47 (1.6% above fair value)
Industry Position: 87.7% above the Medical Distribution median (#74 of 94)
No single metric tells the full story. See the HSIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
81GF Score
Get the complete analysis for HSIC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSIC has been successfully added to your 
